industry funds

IFM Therapeutics is a privately held biopharmaceutical company focused on developing small-molecule therapies that modulate the innate immune system to treat cancer, autoimmunity, and inflammatory diseases. The company utilizes a unique "incubator" model, spinning out subsidiary companies (such as IFM Tre, IFM Due, and IFM Quattro) focused on specific biological targets like NLRP3 and STING. This strategy has led to significant high-value acquisitions by major pharmaceutical companies, including Bristol Myers Squibb and Novartis. By targeting the body's first line of defense, IFM aims to address high unmet needs in chronic inflammatory conditions and oncology.